Tvardi Therapeutics, Inc.
TVRD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001346830
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
57
- −10 vs. Q1 2026
- Total value $4.24M
Superinvestors holding TVRD
0
- None of the superinvestors held TVRD at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by TVRD insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2025 | Feb 28, 2025 | Posner ChristopherPRESIDENT AND CEO | SSaleCommon Stock | −583 | $4.75 | −$2.77K | 13.11K | −4.3% | SEC |
| Mar 4, 2025 | Feb 28, 2025 | Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C. | SSaleCommon Stock | −163 | $4.76 | −$775.88 | 7.19K | −2.2% | SEC |
| Feb 6, 2025 | Feb 4, 2025 | Posner ChristopherPRESIDENT AND CEO | SSaleCommon Stock | −372 | $4.72 | −$1.76K | 13.69K | −2.6% | SEC |
| Nov 6, 20244:51 PM ET | Nov 4, 2024 | Posner ChristopherPRESIDENT AND CEO | SSaleCommon Stock | −3.67K | $0.29 | −$1.06K | 168.77K | −2.1% | SEC |
| Aug 2, 20244:05 PM ET | Aug 1, 2024 | Posner ChristopherPRESIDENT AND CEO | SSaleCommon Stock | −4.15K | $0.35 | −$1.45K | 172.44K | −2.3% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in TVRD at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Slate Path Capital LP | 704,118 | $1.34M | 0.02% | 00.0% | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | 344,382 | $654.33K | 0.00% | −326−0.1% | Reduced |
| AMERICAN FINANCIAL GROUP INC | 223,659 | $424.95K | 0.15% | 00.0% | Unchanged |
| UBS Group AG | 111,133 | $211.15K | 0.00% | +60,679+120.3% | Added |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 101,034 | $191.97K | 0.00% | 00.0% | Unchanged |